{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment&page=2", "query": { "intervention": "Combination Treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-21T21:07:24.052Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01533259", "title": "Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acquired Immunodeficiency Syndrome", "HIV Infections" ], "interventions": [ { "name": "Stribild", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2012-01", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-01-26", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 9, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533259" }, { "nct_id": "NCT03600480", "title": "A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "NNC0174-0833", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo (NNC0174-0833)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 96, "start_date": "2018-07-25", "completion_date": "2020-06-12", "has_results": false, "last_update_posted_date": "2021-11-17", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03600480" }, { "nct_id": "NCT02004262", "title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Aduro Biotech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 303, "start_date": "2014-02-05", "completion_date": "2016-08-23", "has_results": true, "last_update_posted_date": "2018-06-04", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02004262" }, { "nct_id": "NCT03459846", "title": "A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 154, "start_date": "2018-03-16", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Fort Myers, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03459846" }, { "nct_id": "NCT00005946", "title": "Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005946" }, { "nct_id": "NCT03647488", "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Capmatinib", "type": "DRUG" }, { "name": "Spartalizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2018-12-26", "completion_date": "2020-09-07", "has_results": true, "last_update_posted_date": "2022-01-24", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 1, "location_summary": "Fayetteville, Arkansas", "locations": [ { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647488" }, { "nct_id": "NCT00565227", "title": "Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small-Cell Lung Carcinoma", "Prostate Cancer", "Bladder Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "vorinostat (suberoylanilide hydroxamic acid)", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-04", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2016-12-02", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00565227" }, { "nct_id": "NCT00289783", "title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Haemophilus Influenzae Type b", "Neisseria Meningitidis" ], "interventions": [ { "name": "GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine", "type": "BIOLOGICAL" }, { "name": "ActHIB", "type": "BIOLOGICAL" }, { "name": "PedvaxHIB", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Prevnar", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "15 Months", "sex": "ALL", "summary": "6 Weeks to 15 Months" }, "enrollment_count": 4441, "start_date": "2006-02-22", "completion_date": "2008-02-26", "has_results": true, "last_update_posted_date": "2018-08-24", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 88, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00289783" }, { "nct_id": "NCT05067283", "title": "A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Calderasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2021-12-17", "completion_date": "2030-02-25", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 6, "location_summary": "Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067283" }, { "nct_id": "NCT00041483", "title": "Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Anecortave Acetate 15 mg sterile suspension", "type": "DRUG" }, { "name": "Photodynamic Therapy (PDT)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alcon Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 530, "start_date": "2002-06", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2014-07-01", "last_synced_at": "2026-09-21T21:07:24.052Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041483" } ] }